Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2019
Price : $35 *
At a glance
- Drugs Aglatimagene besadenovec (Primary) ; Nivolumab (Primary) ; Temozolomide (Primary) ; Valaciclovir (Primary)
- Indications Glioma
- Focus Adverse reactions; First in man; Proof of concept
- 02 Oct 2019 Planned End Date changed from 5 Jan 2022 to 28 Feb 2021.
- 21 Mar 2019 According to a Candel Therapeutics, the company announced the initiation of accrual.
- 07 Feb 2019 Status changed from active, no longer recruiting to recruiting.